Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2017 (2017), Article ID 6275987, 8 pages
https://doi.org/10.1155/2017/6275987
Research Article

Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients

1Department of Microbiology, Faculty of Medicine Foca, University of East Sarajevo, Sarajevo, Bosnia and Herzegovina
2Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
3Department of Infectology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
4Department of Surgery, Faculty of Medicine Foca, University of East Sarajevo, Sarajevo, Bosnia and Herzegovina

Correspondence should be addressed to Ivan Jovanovic

Received 29 December 2016; Revised 24 February 2017; Accepted 26 February 2017; Published 11 April 2017

Academic Editor: Giuseppe Murdaca

Copyright © 2017 Ruzica Lukic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Hepatitis C virus infection (HCV), one of the greatest causes of liver disease, is a frequent complication in patients with end-stage renal disease (ESRD) on dialysis. ESRD is defined as decreased glomerular filtration and also accompanied by impaired function of the immune system. Galectin-3 is a β-galactoside-binding lectin, involved in various biological processes including pathogenesis of chronic renal disease. The aim of our study was to estimate disease severity in ESRD HCV+ patients and analyze the serum concentrations of IL-1β, IL-4, IL-23, and IL-6; anti-HCV antibodies; and galectin-3. Also, we attempted to determine potential correlation between galectin-3 level and parameters of disease severity ALT and AST. Our results showed decreased levels of ALT and AST (), demonstrating less liver destruction in ESRD HCV+ patients in comparison to HCV+ patients. Increased levels of IL-6 () implicate a hepatoprotective role of IL-6 in these patients. Also, level of galectin-3 () in the serum of ESRD HCV+ patients was higher than that of HCV+ patients. This alteration was accompanied with negative correlation between galectin-3 and AST and ALT, respectively (; ). The presence of increased systemic levels of IL-6 and Gal-3 in ESRD HCV+ patients may be an attempt to counteract or limit ongoing proinflammatory processes and to downregulate chronic inflammation, suggesting the new aspects of HCV infection in ESRD patients.